T-cell receptor and CD8 co-receptor (TCR and CD8)

The **T-cell receptor and CD8 co-receptor** are integral membrane glycoproteins found on the surface of cytotoxic T lymphocytes. The T-cell receptor (TCR) is responsible for recognizing antigenic peptides presented by major histocompatibility complex class I (MHC-I) molecules, while the CD8 co-receptor binds to the non-polymorphic α3 domain of the same MHC-I molecule, stabilizing the interaction and enhancing signal transduction. TCR consists of α and β polypeptide chains (or γ and δ in a minority of T cells), each with variable and constant regions allowing vast specificity. CD8 exists primarily as either a CD8αβ heterodimer (most conventional CD8+ T cells) or CD8αα homodimer (some intraepithelial lymphocytes), contributing to T cell signaling, thymic selection, and immune cell maturation through association with Src family kinase LCK. These molecules are fundamental to cell-mediated immunity, enabling the detection and elimination of infected or malignant cells. They are frequent therapeutic targets or biomarkers in cancer immunotherapy, infectious disease, and autoimmune conditions due to their central role in regulating adaptive immune responses[1][2][3][4][5][7]. **Note:** - This target name “T-cell receptor and CD8 co-receptor” combines two molecular entities (the TCR and the CD8 co-receptor), both of which are valid immunotherapeutic targets and interact functionally, but each is often considered separately in molecular targeting and classification. Technically, “T-cell receptor” and “CD8 co-receptor” should be structured and described individually for maximal accuracy. If structured information on either is required independently, they should be parsed into two records. - No common single abbreviation or formal combined canonical name exists for the pair; both are discussed as a functional unit but are distinct molecularly. - The main interacting drug class directly targeting this complex are monoclonal antibodies (primarily against CD8, less commonly TCR), while checkpoint inhibitors and cell therapies modulate their function indirectly[2][5].

Other names

TCR and CD8T-cell antigen receptor and CD8TCR/CD8 complex

Monoclonal antibodies can block or modulate CD8 or TCR function to suppress or enhance T cell responses - Checkpoint inhibitors facilitate TCR recognition and signaling by blocking inhibitory signals - CAR-T therapies engineer TCR or utilize CD8 domains for enhanced antigen recognition